Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease.
about
The choreography of neuroinflammation in Huntington's diseaseMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's diseaseHuntington’s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer’s diseaseThe role of microglia in brain maintenance: implications for Rett syndrome.Modeling an autism risk factor in mice leads to permanent immune dysregulation.Mutant huntingtin impairs immune cell migration in Huntington disease.Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntington's disease.Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's diseaseCharacterisation of immune cell function in fragment and full-length Huntington's disease mouse modelsThe role of the immune system in triplet repeat expansion diseasesCerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's DiseasePerivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantationCannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation.HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.Stem cell-based therapy for Huntington's disease.Peripheral inflammation in neurodegeneration.Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.Remission of Psychosis in Treatment-Resistant Schizophrenia following Bone Marrow Transplantation: A Case Report.Loss of the Sexually Dimorphic Neuro-Inflammatory Response in a Transgenic Mouse Model of Huntington's Disease.Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.Mutant huntingtin is present in neuronal grafts in Huntington disease patients.Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease
P2860
Q26828403-B9C26C7F-CDC2-479C-BA19-914A8F2CE732Q27005950-A901EAD4-352C-4E9A-8466-8F9764E99D93Q27316866-1EBDEF93-24DA-4916-859F-1F6E057CF456Q27334472-FC82AD16-8BFC-4B9F-A9E7-52531C4C2226Q29248581-D19E01D8-9755-452F-8623-FCCC5B3694CBQ30414657-B9879768-047A-4774-9427-045E1F001AE2Q30458844-29725154-809F-4315-8904-82B7CCCFFAB0Q30530945-B7B136B6-0403-4C87-8753-03BF973AD85CQ30837903-96B87271-0D2D-446F-A8FF-BB37FDE2DE77Q33614987-6C765525-4BCE-4C25-830E-AE37C2C9F140Q34674235-6C4B3699-748E-4F0D-A9D9-A93EB334D31EQ35271805-1423F714-59C1-49A0-9EB7-D4539D418A12Q36140894-373EBAB6-DB94-45D7-A8EA-D42A308B12BFQ36997172-E802A51C-2D0A-4F41-BDDA-88128D724492Q37120339-6574B1C6-4F6F-45F7-9DFA-DE1075B34EDBQ37169655-1A35F74E-72F6-4EDD-BB67-570AB48309D9Q37345118-78D3E076-0AE4-42E8-BDFA-5EB711C656F8Q37530090-A0E19270-4687-4E6E-9D01-4493A12FDD11Q37697482-BADD7881-5286-4828-AF98-075BEAFBE2E2Q38055455-E4A6C263-EAFD-4C8F-A9B0-1DB88F76BD82Q38094970-580F100A-5CAC-4214-BA31-CF02CF3BBC89Q39035495-84031D58-D7A9-4546-BEA7-714F853132A3Q39375357-2393122F-1E05-40E1-AB6E-1B2F38A38338Q41898391-90DB8E23-390B-435A-A94A-BC69F241C967Q42363818-A045FF80-6BB6-4FDC-9FFC-99B61C7DCBD1Q45291463-AF771DD5-9347-4986-B0E4-46E5091F2732Q45298602-CFD99CB7-FAB9-4543-8409-159315CAD1F9Q45299114-B8740BF0-1545-4CD3-B180-04314A633C72Q45305215-AD2BD088-48C1-4428-8306-306CBC593EC1Q45305684-BAEF293D-ADE4-4B9A-B66A-667C76722872Q57877015-0B68CC76-4748-4416-8414-DAC3B13F88F0
P2860
Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bone marrow transplantation co ...... odels of Huntington's disease.
@ast
Bone marrow transplantation co ...... odels of Huntington's disease.
@en
type
label
Bone marrow transplantation co ...... odels of Huntington's disease.
@ast
Bone marrow transplantation co ...... odels of Huntington's disease.
@en
prefLabel
Bone marrow transplantation co ...... odels of Huntington's disease.
@ast
Bone marrow transplantation co ...... odels of Huntington's disease.
@en
P2093
P2860
P1476
Bone marrow transplantation co ...... odels of Huntington's disease.
@en
P2093
Anna Magnusson
Anthony Adame
Austin Chou
Maria Björkqvist
Monica J Carson
Paul J Muchowski
Richard Ransohoff
Shinichi Kohsaka
Thomas Möller
Wanda Kwan
P2860
P304
P356
10.1523/JNEUROSCI.4846-11.2012
P407
P577
2012-01-01T00:00:00Z